Maze Therapeutics has revealed topline phase 2 data for its lead kidney disease candidate that has analysts heralding its “best-in-class potential.” The once-daily oral small molecule APOL1 inhibitor, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results